Controlled release corticosteroid compositions and methods...

Details Controlled release corticosteroid compositions and methods... Controlled release corticosteroid compositions and methods...

2009-05-14

2011-10-04

Padmanabhan, Sreeni (Department: 1627)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Cyclopentanohydrophenanthrene ring system doai

C514S772100

Reexamination Certificate

active

08030297

ABSTRACT:
Disclosed herein are compositions and methods for the treatment of otic disorders with steroid, NSAID, and/or adenosine triphosphatase (“ATPase”) modulator agents. In these methods, the steroidal, NSAID, and/or ATPase compositions and formulations are administered locally to an individual afflicted with an otic disorder, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).

REFERENCES:
patent: 4188373 (1980-02-01), Krezanoski
patent: 4478822 (1984-10-01), Haslam et al.
patent: 5292516 (1994-03-01), Viegas et al.
patent: 5503848 (1996-04-01), Perbellini et al.
patent: 6284804 (2001-09-01), Singh et al.
patent: 6359016 (2002-03-01), Singh et al.
patent: 6392036 (2002-05-01), Karlsson et al.
patent: 6509327 (2003-01-01), Cagle et al.
patent: 6548527 (2003-04-01), Rahman et al.
patent: 6740664 (2004-05-01), Cagle et al.
patent: 7220431 (2007-05-01), Sawchuk et al.
patent: 7524834 (2009-04-01), Karlsson et al.
patent: 2001/0034339 (2001-10-01), Singh et al.
patent: 2003/0092776 (2003-05-01), Ron et al.
patent: 2003/0139382 (2003-07-01), Wall et al.
patent: 2004/0082509 (2004-04-01), Bonny
patent: 2004/0101560 (2004-05-01), Sawchuk et al.
patent: 2005/0214338 (2005-09-01), Guitton et al.
patent: 2006/0013858 (2006-01-01), Trune
patent: 2006/0046970 (2006-03-01), Bowman et al.
patent: 2006/0063802 (2006-03-01), Guitton et al.
patent: 2006/0264897 (2006-11-01), Lobl et al.
patent: 2007/0065374 (2007-03-01), Liversidge et al.
patent: 2007/0178051 (2007-08-01), Pruitt et al.
patent: 2009/0156566 (2009-06-01), Wall et al.
patent: WO 97/038698 (1997-10-01), None
patent: WO 99/024051 (1999-05-01), None
patent: WO-02-056890 (2002-07-01), None
patent: WO 03/034979 (2003-05-01), None
patent: WO 03/071986 (2003-09-01), None
patent: WO 2006/099325 (2006-09-01), None
patent: WO2006102964 (2006-10-01), None
patent: WO 2007/031098 (2007-03-01), None
patent: WO 2007/031280 (2007-03-01), None
patent: WO 2007/037874 (2007-04-01), None
patent: WO 2007/037886 (2007-04-01), None
patent: WO 2007/038949 (2007-04-01), None
patent: WO-2008-001341 (2008-01-01), None
patent: WO 2008/076556 (2008-06-01), None
Salt et. al., Drug Discovery Today, 2005, NIH, vol. 10, No. 19, pp. 1299-1306.
Hall et. al., Antimicrobial Agents and Chemotherapy, 1998, American Society for Microbiology, vol. 42, No. 4, pp. 666-674.
McCarthy et. al., Clinical Eye and Vision Care, 2000, Elsevier, vol. 12, pp. 139-150.
Dourmishev et. al., International Journal of Dermatology, 1999, Blackwell Science, vol. 38, pp. 656-663.
Nance et. al., Mental Retardation and Developmental Disabilities, 2003, Wiley-Liss, vol. 9, pp. 109-119.
Karolewicz and Pluta, “Thermosensitive polymers in drug form technology II. Possibilities of use of thermosensitive polymers as active substance carriers,” Polimery W Medycynie 38(1):15-26, 2008 (English language abstract).
Bird et al., “Intratympanic versus intravenous delivery of methylprednisolone to cochlear perilymph,” Otology & Neurotology 28(8):1124-1130, 2007.
PCT/US2009/003066 International Search Report mailed Jan. 5, 2010.
Wang et al., “Pharmacokinetic and toxicity profile of the clinical candidate OTO-104: a sustained release dexamethasone hydrogel for inner ear delivery,” Abstract, COSM Meeting, May 1-2, 2010.
Wang et al., “Dose-dependent sustained release of dexamethasone in inner ear cochlear fluids using a novel local delivery approach,” Audiol Neurotol 14:393-401, 2009.
Wang et al., “Pharmacokinetic and safety profile of OTO-104: a sustained release dexamethasone hydrogel for inner ear delivery,” Abstract, ARO Meeting , Feb. 6-10, 2010.
Piu et al., “Towards predicting human inner ear pharmacokinetics: allometric scaling using guinea pigs and sheep,” Abstract, ARO Meeting , Feb. 6-10, 2010.
PCT/US2009/067552 international search report mailed Aug. 18, 2010.
Dellamary et al., “Development of poloxamer hydrogel formulations for sustained inner ear drug delivery,” Abstract, 2010 AAPS National Biotechnology Conference in San Francisco.
Dellamary et al., “Assessing and optimizing osmolality of poloxamer 407 hydrogel formulations for sustained inner ear drug delivery,” Abstract, 2010 AAPS National Biotechnology Conference in San Francisco.
Dellamary et al., “Novel poloxamer hydrogel formulations for sustained drug delivery to the middle ear,” Abstract, 2010 AAPS Annual Meeting in New Orleans, Nov. 14-Nov. 18.
Dellamary et al., “Novel poloxamer hydrogel formulations for sustained inner ear drug delivery,” Abstract, Controlled Release Society 37th Annual Meeting and Exposition in Portland Jul. 10-14, 2010.
Dellamary et al., “Development of poloxamer hydrogel formulations for sustained inner ear drug delivery,” Poster, 2010 AAPS National Biotechnology Conference in San Francisco.
Dellamary et al., “Assessing and optimizing osmolality of poloxamer 407 hydrogel formulations for sustained inner ear drug delivery,” Poster, 2010 AAPS National Biotechnology Conference in San Francisco.
Dellamary et al., “Sustained drug delivery to the middle ear via a novel poloxamer hydrogel formulation,” Poster, 2010 AAPS Annual Meeting in New Orleans, Nov. 14-Nov. 18.
Dellamary et al., “Novel poloxamer hydrogel formulations for sustained inner ear drug delivery,” Poster, Controlled Release Society 37th Annual Meeting and Exposition in Portland Jul. 10-14, 2010.
Piu, “OTO-104: a sustained release dexamethasone hydrogel formulation for the treatment of Meniere's disease,” Oral presentation title; Recent topics in Meniere's disease treatment, Nov. 16, 2010.
Wang et al, “Pharmacokinetic and toxicity profile of OTO-104—a sustained release,” ARO MidWinter meeting, Abstract 644, Feb. 8, 2010.
Wang et a1, “Pharmacokinetic and toxicity profile of the clinical candidate OTO-104: a sustained release dexamethasone hydrogel for inner ear delivery,” 2010 Abstracts selected for AOS spring meeting, Las Vegas, NV, May 1-2, 2010.
Wang et al., “Pharmacokinetics of dexamethasone solution following intratympanic injection in guinea pig and sheep,” Audio Neurotol 16:233-241, 2010.
Mostafa, “Transtympanic Membrane Delivery of Antibiotics-Pharmacokinetic Studies in Chinchillas,” Dissertation submitted to the Graduate School of the University of Minnesota in Mar. 2007.
Ahn et al., “Lipoic acid rescues DBA mice from early-onset age-related hearing impairment,” Neuroreport 19(13):1265-9, 2008.
Arnold et al., “Novel slow- and fast-type drug release round-window microimplants for local drug application to the cochlea: an experimental study in guinea pigs,” Audiol Neurootol 10(1):53-63, 2005.
Auris Medical, press release reporting initiating of phase I/II clinical trial with AM-101, Feb. 22, 2007.
Auris Medical, press release reporting results of phase I/II clinical trial with AM-111, Jun. 21, 2006.
Battaglia et al., “Combination therapy (intratympanic dexamethasone+high-dose prednisone taper) for the treatment of idiopathic sudden sensorineural hearing loss,” Otol Neurotol 29(4):453-60, 2008.
Campbell et al., “Oral-D-methionine (MRX-1024) significantly protects against cisplatin-induced hearing loss: a phase II study in humans,” Abst 32ndAnn MidWinter Res Meeting, ARO Abstracts 32:7, Feb. 14-19, 2009.
Chen and Nathans, “Estrogen-related receptor beta/NR3B2 controls epithelial cell fate and endolymph production by the stria vascularis,” Dev Cell 13(3):325-37, 2007.
Chen et al., “Design and preparation of thermosensitive in situ gel of dexamethasone sodium phosphate,” J Guangdong Coll Pharm 23(5):518-21, 2007 (English abstract).
Chen et al., “Evaluation of thermosensitive in situ gel using dynamic rheological experiment,” Chin Pharm J 43(6):444-447, 2008 (English abstract).
Chen et al., “In vivo dis

Affiliated with

Also associated with

Rating

Controlled release corticosteroid compositions and methods... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Controlled release corticosteroid compositions and methods..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Controlled release corticosteroid compositions and methods... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4281515